Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

• Status: Completed
• Trial end date: 2017-06-28

Summary

The goal of this clinical research study is to learn if the combination of clofarabine, idarubicin, and cytarabine, or the combination of fludarabine, idarubicin, and cytarabine can help control Acute myeloid leukemia (AML) and Myelodysplastic syndromes (MDS). The safety of these study drug combinations will also be studied.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Treatments: Clofarabine; Cytarabine; Fludarabine; Fludarabine phosphate; Idarubicin; Vidarabine